Gossamer Bio reports 90.5% participation in convertible note exchange Jun 3, 2026 08:01AM
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes Jun 3, 2026 08:00AM
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes Jun 2, 2026 08:00AM
Gossamer Bio launches debt exchange offer to eliminate $120 million May 18, 2026 07:06AM
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support May 18, 2026 07:05AM


May 18, 2026 07:00AM Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
Mar 23, 2026 03:12AM Cantor Fitzgerald Downgrades Gossamer Bio Inc. (GOSS) to Neutral
Jan 22, 2026 07:45AM Gossamer Bio (GOSS) Reiterated at Overweight by Cantor Fitzgerald: Phase 3 Readout in Feb
Nov 13, 2025 07:29AM Gossamer Bio's (GOSS) Seralitinib Data Likely Comes Out by Feb - Cantor Fitzgerald
Sep 11, 2025 06:49AM Cantor Fitzgerald Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)
May 16, 2025 06:45AM Cantor Fitzgerald Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)
Sep 10, 2020 07:07AM Gossamer Bio Announces Participation in Upcoming Investor Conferences
Jul 14, 2020 06:27AM Gossamer Bio Inc. (GOSS) PT Raised to $33 at Cantor Fitzgerald; 'GB004 has best-in-class potential'
May 19, 2020 09:30AM Pre-Open Stock Movers 05/19: (ABUS) (DVAX) (AAP) Higher; (BLPH) (GMDA) (GOOS) Lower (more...)
May 18, 2020 05:44PM After-Hours Stock Movers 05/18: (ABUS) (DAC) (BIDU) Higher; (BLPH) (GMDA) (GOSS) Lower (more...)
Dec 17, 2019 06:34AM Gossamer Bio Inc. (GOSS) PT Lowered to $25 at Cantor Fitzgerald
Dec 6, 2019 06:20AM Cantor Fitzgerald Starts Gossamer Bio Inc. (GOSS) at Overweight